Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
The FDA said Eli Lilly’s weight-loss drugs were no longer in shortage on Oct. 2, preventing pharmacies from making cheaper ...
Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...
The Food and Drug Administration on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide ... compounding pharmacies would no longer be permitted to manufacture and ...
Oct 7 (Reuters) - A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s (LLY.N), opens new tab blockbuster weight ...
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
Growth for its GLP-1 weight loss drugs continues to be robust. The drugs' removal from the shortage list is ... Mounjaro was Eli Lilly's best-selling drug in the second quarter with sales of ...
The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight ...
The Danish drugmaker’s arch-rival Eli Lilly & Co. has introduced another shot ... the diabetes shot that’s often ...
Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...